Posted by Michael Wonder on 29 Mar 2021
Saxenda recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years
26 March 2021 - Novo Nordisk today announced that the CHMP under the EMA has recommended that the use of Saxenda is expanded for the treatment of obesity in adolescents aged 12–17 years.
If approved, Saxenda will be the first EU approved treatment for obesity in adolescents. Saxenda would be approved for the treatment of adolescents with obesity, with an initial body mass index corresponding to ≥30 kg/m2 for adults and a body weight above 60 kg, in combination with healthy eating and increased physical activity.
